Navigation Links
Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
Date:9/13/2007

AMSTERDAM, September 13 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announced today that it has appointed Hessel J. H. M. Lindenbergh as Chairman of its Supervisory Board.

Hessel Lindenbergh is a former member of the managing board of ING Group N.V.. Currently, Mr. Lindenbergh is chairman of the supervisory board of NIB Capital N.V. and board member of the Royal Numico, Petroplus International and Gamma Holding. Mr. Lindenbergh is also a member of the board of directors of the University of Amsterdam (UvA) and Senior Counsel at the Boer & Croon.

Agendia's other supervisory board directors are Prof. Dr. Wim van Harten from the Netherland's Cancer Institute (NKI), Pieter van der Meer from Gilde Health Care, Gertjan van der Baan from van Herk Biotech B.V., and Dr. Gosse Bruisma, an independent member.

In making this announcement, Agendia's CEO, Dr. Bernhard Sixt, stated: "We are very pleased that Mr. Hessel Lindenbergh has accepted the chair of the company's Supervisory Board bringing along a tremendous international reputation in the financial business. We are convinced that our Supervisory Board will contribute to further build the company strategically and to accelerate the commercial success of Agendia."

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(i), is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation.

Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

(i) CupPrint(R) is based on a license to the TUA database of AviaraDx

(ii) RNAretain(R) is a trademark of Asuragen Inc.


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a ... Seymour , MD, MPH, will present information about the company,s programs ... in New York City . ... Windsor Room at 5:30PM EST. Registered attendees can request a one ... City . --> New York City ...
(Date:2/6/2016)... McLean, VA (PRWEB) , ... February 06, 2016 , ... ... enrichment session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... be held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in ...
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
Breaking Biology Technology:
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
Breaking Biology News(10 mins):